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is a novel predictor associated with poor
prognosis in Acute Myeloid Leukemia
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Abstract
Background: Depletion of Poly-C binding protein-1(PCBP1) is implicated in various human malignancies. However,
the underlying biological effect of PCBP1 in cancers, including acute myeloid leukemia (AML), still remains elusive.
The purpose of this study was to examine the expression and clinical outcome of PCBP1in acute myeloid leukemia.
Methods: Bone marrow fluids of 88 newly diagnosed AML patients were sampled, and the PCBP1 mRNA expression
level was evaluated using quantitative RT-PCR. The association between PCBP1 expression and clinicopathological
features or the survival status of the patients was assessed by Chi-square test and Kaplan-Meier method.
Results: Comparing newly diagnosed AML patients to normal healthy donors, PCBP1 expression was significantly
decreased in AML patients (P < 0.001). Conversely, PCBP1 expression had accordingly recovered back to normal in
patients with complete remission (P < 0.001). Clinical feature analyses showed that PCBP1 expression was
negatively correlated with white blood cell count (P = 0.024). In addition, patients with low PCBP1 expression
had poor disease-free survival (11.8 % vs. 45.3 %; P = 0.01) and overall survival (18.2 % vs. 42.4 %; P = 0.032),
respectively.
Conclusions: Taken together, our results showed for the first time that expression of PCBP1 was down-regulated in
newly diagnosed AML patients and might be an independent prognostic marker in AML and should to be further
investigated.
Background
Acute myeloid leukemia (AML) is a clinically and genetic-
ally heterogeneous disease characterized by the differenti-
ation arrest and the malignant clonal proliferation of
hematopoietic progenitor cells [1, 2]. It is the most com-
mon myeloid leukemia and accounts for 70 % of acute
leukemia in adults [3–5]. Exposure to ionizing radiation,
benzene, and cytotoxic chemotherapy is known to in-
crease the incidence of AML [3]. The pathogenesis of
AML is highly complex. Over the past decades, research-
ing in genetic alterations, such as FLT3, NPM1, CEBPA
gene mutations, resulted in prodigious improvement in
the pathogenesis, prognostic classification and novel
therapeutic approaches of AML [6, 7]. Despite the note-
worthy progress in the development of genomic studies
on AML, the prognosis classification and treatment for
most AML patients still remains unsatisfactory [7–10].
More than half of young adult patients and about 90 % of
elder patients still die of the disease, due to either resist-
ance to therapy or relapsed AML, and the 5-year survival
rate is less than 30 % [11–13]. As a result, more effective
gene signatures are still required for risk-adapted treat-
ment [14]. In addition, clinical outcomes can differ greatly
in patients with identical karyotypes, suggesting that add-
itional factors on AML diagnosis and prognosis should be
identified and clarified [12]. Thus, investigation for more
valuable diagnostic, prognostic factors and therapeutic tar-
gets implicated in AML pathogenesis is pressing for the
performance of individual antitumor treatment.
Poly-C binding protein 1, also referred to as hnRNP-E1
or αCP-1 [15], is broadly expressed in many human tissues
and organs, including bone marrow, as well as the liver,
heart, kidneys, brain, lungs, and placenta. Functionally,
PCBP1 is known to play multiple roles in a wide spectrum
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of transcriptional and posttranscriptional events, including
in mRNA transcription regulation, transportation, splicing,
translation, and stabilization by means of its cis-DNA/
RNA-binding activity [16–18]. Increasing clinical and cel-
lular evidence has demonstrated that PCBP1 plays pivotal
roles in multiple pathological processes, including cancer
apoptosis, metastasis, invasion and malignant transform-
ation [17, 19–21]. Recently, some studies indicated that
aberrant expression of PCBP1 is associated with poor
prognosis [22], and low PCBP1 expression could be a poor
prognosis marker in diverse human cancers [17, 23].
Although aberrant PCBP1 expression levels are associ-
ated with cancer progression and metastases in many
human solid cancers, there is not a straightforward ex-
periment to demonstrate this role in tumor formation.
Likewise, the function of PCBP1 in leukemia, including
AML remains elusive. Herein, our study was carried out
to investigate PCBP1 expression in AML and to under-
stand the prognostic role of PCBP1 in AML patients.
Methods
Patients and tissue samples
A myeloid neoplasm with 20 % or more myeloblasts in
the peripheral blood or bone marrow is considered to be
AML according to the 2008 World Health Organization
(WHO) criteria [24]. Initial diagnosis of AML samples
prior to AML treatment were collected as newly diag-
nosed of acute myeloid leukemia. 88 patients, who were
newly diagnosed with AML, were admitted for treatment
at the First Affiliated Hospital of Sun Yat-sen University
from 2012 to 2015. All patients underwent a bone
marrow puncture at the time of diagnosis, with a
signed informed consent. Morphology, Immunology,
Cytogenetics and Molecular Biology (MICM) classifi-
cation was performed on the bone marrow. Clinical
features of all patients were summarized in Table 1,
and the risk status was predicted on the basis of
validated cytogenetics and molecular abnormalities.
According to NCCN guidelines version 2.2013, we
classified acute myeloid leukemia risk-status into three
categories: better-risk (inv(16),t(16;16),t(8;21),t(15;17)
or NPM1 mutation in the absence of FLT3-ITD with
normal cytogenetics), poor-risk (complex monosomal
karyotype, −5, 5q-,-7,7q-,11q23 abnormality, inv(3),
t(3;3), t(6;9), t(9;22) or normal cytogenetics with FLT3-
ITD mutation) or intermediate-risk (neither better-risk
nor poor-risk). Meanwhile, 24 healthy donors were re-
cruited as normal control with their permission.
Complete remission (CR) was defined by the presence
of all the following: less than 5 % myeloid blasts in
bone marrow, no leukemic blasts in peripheral blood,
absolute neutrophil counts ≥ 1,500/μl and platelet
counts ≥ 100,000/μl in peripheral blood, and no per-
sistence of extramedullary disease [25]. The clinical
characteristics of these newly diagnosed patients were
listed in Table 1. Sixty-seven patients were further
followed up. In analysis of the disease-free survival,
data were censored at the time of relapse, death or the
last contact; in analysis of the overall survival, data
were censored when the patients died or last known
to be alive. This study was approved by the local
ethic committee of the First Affiliated Hospital of Sun
Yat-sen University and informed consents were ob-
tained from each patient.
Preparation of mononuclear cells and RNA extraction
Bone marrow fluid from each patient was obtained using
a 6-ml EDTA-containing vacutainer. The collected sample
was then diluted with physiological saline in 1:1 propor-
tion, the diluted sample was carefully layered over the
ficoll lymphocyte separation medium (LSM, MP Biomedi-
cals, USA) and centrifuged at a speed of 400 × g at room
temperature for 20 minutes. During centrifugation, differ-
ential migration results in the formation of four cell layers:
plasma layer, mononuclear cell layer, LSM layer and RBC
pellet. Erythrocytes and polynuclear leukocytes sedimen-
ted to the bottom of the tube; mononuclear cells were
found at the plasma-LSM interface. After aspirating the
mononuclear cells and transferring them to a new centri-
fuge tube, cells were washed twice with buffered balanced
salt solution and re-suspended in 1 ml TRIzol reagent
(Cwbio Cat: CW0580A). Total cellular RNAs were then
extracted according to the guideline of the Ultrapure RNA
Kit (Cwbio Cat: CW0581, China) and eluted in 30–50 μl
of RNase-free water. The RNA concentration and quality
were determined by NanoDrop 1000 spectrophotometer
(ThermoFisher Scientific, USA).
Table 1 Characteristics of AML patients in this study
Variables No. of patients (%)
Age, (range, year old) 41 (14-79)
Sex ration, male/female 61/27
Median wbc, ×109/L,(range) 24.96 (0.85-395)
Blast cell in bone marrow, % (range) 56 (20-96)
FAB category:
M0/M1 8 (9.09 %)
M2 19(21.59 %)
M3 11(12.5 %)
M4/M5 44(50.0 %)
M6/M7 6(6.82 %)
Risk status:
Better-risk 21(23.86 %)
Intermediate-risk 44(50.0 %)
Poor-risk 23(26.14 %)
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Reverse transcription
To obtain cDNA, 2 μg of total RNA were diluted into
nuclease-free water to a total volume of 12 μl, mixed
with 1 μl of anchored-oligo (dT) 18 primer (2.5 μM) and
incubated for 10 minutes at 65 °C to denature the
template-primer mixture. After that, the remaining com-
ponents of the RT mix, 4 μl transcriptor RT reaction
buffer (5×), 0.5 μl protector RNase inhibitor (40 U/ul),
2 μl deoxynucleotide Mix (10 mM) and 0.5 μl transcrip-
tor reverse transcriptase (20 U/μl) were added to the
tube. The 20 μl reaction volumes were incubated at
55 °C for 30 minutes followed by 5 minutes at 85 °C,
and the reaction was then halted by placing the tube
on ice. All cDNAs were diluted to 1:10 in nuclease-free
water and stored at -20 °C for use.
Quantitative real-time PCR analysis for PCBP1 expression
In order to quantify PCBP1 mRNA expression levels,
primers 5’-CATCCGCTAAGAATTTAAAAAT-3’ (for-
ward) and 5’-AAGACAGCAATTCCCAGC-3’ (reverse)
were used. Meanwhile 5’-ACCACAGTCCATGCCATCA
C-3’ (forward) and 5’-TCCACCACCCTGTTGCTGTA-3’
(reverse) were used for amplification of the internal
control gene GAPDH. Quantitative real-time PCR
(qRT-PCR) were performed according to the instruc-
tions of RealMasterMix (SYBR Green) kit (Tiangen
Biotech, China). Briefly, in each total volume of 20 μl reac-
tion mixture, 9 μl of 2.5 × RealMasterMix/20 × SYBR
Solution, 0.4 μl of forward and reverse primers(10 μM),
2 μl of diluted cDNA and 8.2 μl of ultrapure water were
added. Amplification was conducted on a CFX96 Real-
time fluorescent quantitative PCR detection system
(Bio-Rad, USA) with the thermal cycling parameters as
the initial denaturation at 95 °C for 2 minutes, follow-
ing by 40 cycles of 20 seconds at 95 °C, 30 seconds at
60 °C, 40 seconds at 68 °C. Melting curves were drawn
to identify the specificity of the PCR primers. Each ex-
periment was repeated at least for three times.
Relative quantification of PCBP1 expression was cal-
culated by the comparative cycle threshold method (the
2-ΔΔCT method) [26], where ΔΔCT=ΔCT,Target - ΔCT,Control.
The change in expression of PCBP1 was normalized to its
internal control GAPDH, just as ΔCT,Target = CT,Target -
CT,GAPDH. Meanwhile, the smallest numeric values of
2-ΔCT, Target was defined as “1” as a control; the relative
PCBP1 mRNA expression of other AML sample, CR
patients and healthy donors were carried out by folds
of the control.
Statistical analysis
Statistical analysis was performed by SPSS12.0 statis-
tical software. The data was expressed as the mean ±
standard deviation (SD) or mean ± SEM of at least 3
independent experiments. The Student T test was used
to compare continuous variables. Different frequencies
between groups were compared by the chi-square test
or the Fisher exact test. Survival curves were obtained
by the Kaplan-Meier method, and differences in sur-
vival among groups were analyzed by the log-rank
test. P values < 0.05 were considered statistically
significant.
Results
PCBP1 was significantly down-regulated in newly
diagnosed AML patients
In order to explore whether PCBP1 is aberrantly expressed
in AML patients, total RNA was isolated from bone mar-
rows of AML patients and healthy donors, and the relative
expression level of PCBP1 was detected using quantitative
RT-PCR (qRT-PCR). The averaged relative value of
PCBP1expression in newly diagnosed AML patients (aver-
aged expression value 7.08, n = 88) was significantly lower
than that in normal controls (averaged expression value
19.31, n = 24) (Fig. 1, P < 0.001). Furthermore, among 12
patients who achieved CR after one or two cycles of
chemotherapy, PCBP1 expression level had markedly re-
covered back to their initial admission level (mean, 20.96
versus 6.25) (Fig. 2, P < 0.001), although it was higher than
that of the normal controls, there was no statistical differ-
ence (mean 20.96 versus 19.31, p > 0.05) (Fig. 3). Therefore,
the results revealed that PCBP1 expression level in the ma-
jority of AML patients was negatively related to the state of
the illness of AML.
Fig. 1 PCBP1 was down-regulated in AML patients.The relative
PCBP1 mRNA expression in newly diagnosed AML patients (n = 88)
and healthy donors (n = 24) by qRT-PCR evaluation. PCBP1 expression
was significantly decreased in newly diagnosed AML patients (average
7.08) compared with healthy donors (average 19.31; P < 0.001). Each
experiment was performed at least in triplicate
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Low PCBP1 expression was associated with advanced
AML clinical characteristics
To question the relationship of PCBP1 expression to
AML characteristics, the 88 AML patients were classified
into two groups according to the averaged PCBP1 expres-
sion, in which patients with PCBP1 expression value less
than their averaged level (7.08) were classified into low-
expression group (mean expression value 3.12, n = 63),
whereas patients with equal PCBP1 level or above the
mean value were assigned to the high-expression group
(mean expression value 17.06, n = 25), of them, 71.6 %
(63/88) patients showed low PCBP1 expression. PCBP1
expression and clinical features were summarized in
Table 2. The white blood cell count greater than or equal
to 50 × 109/L was identified in 30 (34.1 %) of 88 patients
with AML and the frequency of PCBP1 underexpression
was 86.7 % (26/30) in this subtype, whereas in 58 (65.9 %)
AML patients with leukocyte count less than 50 × 109/L,
only 63.8 % (37/58) cases showed low-pcbp1 expression.
Univariant analysis demonstrated that low PCBP1 expres-
sion was individually associated with high white blood cell
count (P = 0.024). However, there was no significant cor-
relation of PCBP1 expression with other clinical risk-
predicting factors including FAB category (P = 0.413), risk
status (P = 0.143), CD7 expression (P = 0.343), and CD56
expression (P = 0.563) (Shown in Table 2), indicating
PCBP1 could be an independent prognostic marker.
Association of PCBP1 expression to survival of AML
patients
To further investigate the prognostic value of PCBP1 ex-
pression in patients with AML, sixty-seven CR patients
with non-M3 acute myeloid leukemia were followed up.
The effect of PCBP1 expression on non-M3 AML pa-
tients’ survival time was assessed by the Kaplan-Meier
method with the log-rank test. Results revealed that the
low-PCBP1 expression group had a clearly poor disease-
free survival (11.8 % vs. 45.3 %; log rank P = 0.01; shown
in Fig. 4a) and overall survival (18.2 % vs. 42.4 %; log
rank P = 0.032; shown in Fig. 4b), confirming that
PCBP1 could be an additional predictor in AML
prognosis.
Fig. 2 Comparison of PCBP1mRNA expression in 12 newly
diagnosed/complete remission paired samples. Comparison of
PCBP1 mRNA expression of patients in complete remission (CR) with
their initially diagnosed counterparts.PCBP1 expression in patients
achieved CR is 20.96 ± 3.22 versus 6.25 ± 1.72; paired t test, P < 0.001
Fig. 3 Comparison of PCBP1 expression level in CR patients with
normal controls.Comparison of PCBP1 expression in CR patients with
that in healthy donors.CR, 20.96 ± 3.22 versus donors, 19.31 ± 3.3, P > 0.05
Table 2 Association of PCBP1 expression to clinical features
PCBP1 Expression
Variables Cases Sum Low High P
Age <60 76 54 22 1.0
≥60 12 9 3
Sex Male 61 44 17 0.866
Female 27 19 8
WBC <50×109/L 58 37 21 0.024*
≥50×109/L 30 26 4
Blast in BM <50 % 38 28 10 0.704
≥50 % 50 35 15
FAB category M4/M5 44 33 11 0.413
M1/M2 23 14 9
Others 21 16 5
Risk status Better 21 13 8 0.143
Intermediate 44 30 14
poor 23 20 3
CD56 positive 25 19 6 0.563
negative 63 44 19
CD7 positive 20 16 4 0.343
negative 68 47 21
*P < 0.05
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Discussion
Poly(C)-binding proteins (PCBPs), which are also well
known as the heterogeneous nuclear ribonucleoprotein
(hnRNP) family, were initially defined by their sequence-
specific binding ability to polycytosine [poly (C)] in
protein-nucleic acids interaction. In recent years, accumu-
lating evidence has shown that PCBPs play a critical role
in tumor development and progression [27,28]. Among
PCBPs, hnRNP K, PCBP1, and PCBP2 have been inten-
sively studied. HnRNP K, which is overexpressed in di-
verse neoplasms [29], can activate the transcriptional
activation of oncogenes c-SRC and c-Myc [30,31], hinting
its cancer-promoting potential. Upregulation of PCBP2
was also shown in the higher grades of human glioma [32]
and PCBP2 can facilitate gastric cancer growth by
targeting miR-34a [33]. More and more observations
have described that PCBP1 could be implicated in ma-
lignancies [16, 23, 31] via in vitro cell line analyses and
clinical observations. Mechanistically, PCBP1 silence fa-
cilitated androgen receptor (AR) protein expression by
binding to the 3’ untranslated region (UTR) of AR
mRNA in prostate cancer LNCap cells [34]. The phos-
phorylated PCBP1 mediated by TGF β signaling could
promote epithelial-mesenchymal transition [35]. Ac-
cordingly, silencing endogenous PCBP1 in human SH-
SY5Y cells resulted in a large body of altered tran-
scripts, of which some are involved in Wnt signaling
and TGF beta signaling [36]. NF-Kappa B pathway is
also implicated in cancer metastasis, relapse and drug
resistance, and PCBP1 is shown to inhibit NF-Kappa B
activity by interacting with STAT3 pathway in HEK293
cells [37]. Furthermore, the other advances on the bio-
logical function and molecular mechanisms of PCBP1
involving in gene regulation were graphically repre-
sented in Fig. 5 [38]. Recent data disclosed that PCBP1
modulated P63 expression via mRNA stability [39].
Fig. 4 Kaplan-Meier curves of DFS and OS. The Kaplan-Meier survival analysis of the DFS (a) and OS (b) in 67 newly diagnosed non-M3 AML
patients with CR. High PCBP1 group, n = 23; Low PCBP1 group, n = 44, p < 0.05
Fig. 5 Schematic representation of signaling network involving PCBP1. Adapted from Ref. [38]
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Our previous results also demonstrated that PCBP1
downregulates metastatic PRL-3 phosphatase transla-
tion by interacting with its 5’ UTR [17].
It has also been demonstrated that aberrant expres-
sion of PCBP1 promotes tumor development and pro-
gression [19]. Recent studies have revealed PCBP1
could increase the expression of P21WAF1 to reduce cell
proliferation and tumor growth and play as a tumor
suppressor in human solid cancer [17, 40]. In addition,
our previous study had clearly demonstrated that
PCBP1 repressed metastatic PRL-3 translation, result-
ing in the decreased tumorigenic ability of tumor cells
[17]. Interestingly, PRL-3 has been reported to be up-
regulated in de noveo FLT3-ITD-negative AML pa-
tients [41] and involved in AML leukemogenesis [41]
[42], indicating PCBP1 as a tumorsuppressor gene in
AML progression. Our data is comparable with above
reports and found that PCBP1 expression in newly di-
agnosed AML is obviously lower than that observed in
healthy control donors. The results are also well con-
sistent with observations that PCBP1 expressions are
usually downregulated in some human tumors, includ-
ing liver [19], gall bladder [23], choriocarcinoma [22],
colon and lung cancers [17], as well as in metastatic
cervical cancer [21] and metastatic breast cancer cells
[43].Then, we found that the expression of PCBP1 in
12 AML patients in complete remission after intensive
chemotherapy was also markedly increased, compared
to that at their initial diagnosis, suggesting the dysregu-
lated expression of PCBP1 is consistent with cancer
progression. Similar results are also reported in other
studies, such as Pillai MR et al. reported that reduced
PCBP1 expressed in higher grade squamous intrae-
pithelial lesions of cervical tissues and even progressed
to cervical cancer [21].In addition, we analyzed the
clinicopathological factors of PCBP1 in AML. Our re-
sults showed that low level of PCBP1 expression is
positively correlated with the high counts of white cells,
which represented more aggressive clinical features.
The difference in other aggressive clinical features, in-
cluding age, risk status and leukemic blasts, was not
significant. Moreover, when compared to the patients
with high PCBP1 expression, low PCBP1 expression
AML patients have poorer overall and disease-free sur-
vival rates, indicating that PCBP1 expression can be
considered as a novel prognostic marker in initial diag-
nosis of AML. Given that PCBP1 is involved in gene
regulation through multiple roles, including transcrip-
tion, translation and mRNA stabilization. PCBP1
should possibly participate in the blockade of tumori-
genesis by either inhibiting particular oncogene expres-
sion or enhancing tumor suppressor expression in
AML progression. Whatever, the detailed underlying
mechanism of PCBP1 in AML progression will be
further investigated and a potent novel target could be
dug out in the PCBP1-silencing tumors.
To the best of our knowledge, the current study is
the first to demonstrate that PCBP1 is downregulated
in AML patients and accounts for approximately 72 %
of newly diagnosed AML patients compared to healthy
donors. In this study, we screened PCBP1 expression
and defined the average expression level of AML pa-
tients as a cutoff point to classify the patients into 2
groups, of them, 71.6 % (63/88) patients showed low
PCBP1 expression. Similar work for confirming this
novel gene was carried out in lung and colon carcin-
oma [17]. In that study, IHC analysis revealed that
PCBP1protein expression is negative in 85.7 % (54/63)
lung cancer tissue arrays and 91.7 % (66/72) colon can-
cer tissue arrays and the different expression level may be
due to different cancer types. Furthermore, the real risk
changes of PCBP1 downregulation in AML need to be
further investigated.
Conclusion
This study showed that PCBP1 was downregulated in
newly diagnosed acute myeloid leukemia, and the de-
creased PCBP1 expression level was associated with
adverse prognosis in AML. Our findings are well con-
sistent with observations that PCBP1 expression was
usually downregulated in a variety of solid tumors. How-
ever, the underlying molecular mechanism for PCBP1 in
AML progression is not well elucidated and further in-
vestigation will be required.
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